Literature DB >> 11724950

Combination bacteriolytic therapy for the treatment of experimental tumors.

L H Dang1, C Bettegowda, D L Huso, K W Kinzler, B Vogelstein.   

Abstract

Current chemotherapeutic approaches for cancer are in part limited by the inability of drugs to destroy neoplastic cells within poorly vascularized compartments of tumors. We have here systematically assessed anaerobic bacteria for their capacity to grow expansively within avascular compartments of transplanted tumors. Among 26 different strains tested, one (Clostridium novyi) appeared particularly promising. We created a strain of C. novyi devoid of its lethal toxin (C. novyi-NT) and showed that intravenously injected C. novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed surrounding viable tumor cells. When C. novyi-NT spores were administered together with conventional chemotherapeutic drugs, extensive hemorrhagic necrosis of tumors often developed within 24 h, resulting in significant and prolonged antitumor effects. This strategy, called combination bacteriolytic therapy (COBALT), has the potential to add a new dimension to the treatment of cancer.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11724950      PMCID: PMC64999          DOI: 10.1073/pnas.251543698

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Use of preferentially replicating bacteria for the treatment of cancer.

Authors:  M Sznol; S L Lin; D Bermudes; L M Zheng; I King
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Acute tumor lysis syndrome.

Authors:  A Altman
Journal:  Semin Oncol       Date:  2001-04       Impact factor: 4.929

3.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

4.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

Authors:  R B Pedley; S A Hill; G M Boxer; A A Flynn; R Boden; R Watson; J Dearling; D J Chaplin; R H Begent
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

6.  Antitumor effect of Bifidobacterium infantis in mice.

Authors:  Y Kohwi; K Imai; Z Tamura; Y Hashimoto
Journal:  Gan       Date:  1978-10

7.  Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens.

Authors:  A E Bryant; R Y Chen; Y Nagata; Y Wang; C H Lee; S Finegold; P H Guth; D L Stevens
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

Review 8.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Authors:  J M Brown; A J Giaccia
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

9.  Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.

Authors:  M J Lemmon; P van Zijl; M E Fox; M L Mauchline; A J Giaccia; N P Minton; J M Brown
Journal:  Gene Ther       Date:  1997-08       Impact factor: 5.250

10.  Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration.

Authors:  N T Kimura; S Taniguchi; K Aoki; T Baba
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

View more
  143 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  Microorganisms and cancer: quest for a therapy.

Authors:  A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

3.  Synthetic biology for translational research.

Authors:  Peter D Burbelo; Kathryn H Ching; Brian L Han; Caitlin M Klimavicz; Michael J Iadarola
Journal:  Am J Transl Res       Date:  2010-07-20       Impact factor: 4.060

4.  (+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation.

Authors:  Amos B Smith; B Scott Freeze
Journal:  Tetrahedron       Date:  2007-01-07       Impact factor: 2.457

5.  A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy.

Authors:  Kelly Flentie; Brandon Kocher; Seth T Gammon; Deborah V Novack; Jeffrey S McKinney; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

6.  Tumor Microenvironment Targeting Nano-Bio Emulsion for Synergistic Combinational X-Ray PDT with Oncolytic Bacteria Therapy.

Authors:  Wooram Park; Soojeong Cho; Dongkyu Kang; Jun-Hyeok Han; Jung-Hoon Park; Byeongdu Lee; Joonseok Lee; Dong-Hyun Kim
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

7.  Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli.

Authors:  Jung-Joon Min; Hyun-Ju Kim; Jae Hyo Park; Sungmin Moon; Jae Ho Jeong; Yeoung-Jin Hong; Kyoung-Oh Cho; Jong Hee Nam; Nacksung Kim; Young-Kyu Park; Hee-Seung Bom; Joon Haeng Rhee; Hyon E Choy
Journal:  Mol Imaging Biol       Date:  2007-11-10       Impact factor: 3.488

Review 8.  Recent trends and advances in microbe-based drug delivery systems.

Authors:  Pravin Shende; Vasavi Basarkar
Journal:  Daru       Date:  2019-08-02       Impact factor: 3.117

9.  The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.

Authors:  Zhiyu Li; John Fallon; John Mandeli; James Wetmur; Savio L C Woo
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

10.  A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Authors:  Zhiyu Li; John Fallon; John Mandeli; James Wetmur; Savio L C Woo
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.